|Bid||70.00 x 1400|
|Ask||70.16 x 1800|
|Day's range||68.66 - 70.34|
|52-week range||66.34 - 107.26|
|Beta (5Y monthly)||0.60|
|PE ratio (TTM)||23.25|
|Earnings date||01 Aug 2023 - 07 Aug 2023|
|Forward dividend & yield||2.42 (3.51%)|
|Ex-dividend date||20 Apr 2023|
|1y target est||98.18|
CVS Health (NYSE: CVS) is a busy company. It runs the nation's largest drugstore chain with nearly 10,000 locations; it also manages prescription drug plans for employers and insurers; and, through its Aetna division, it provides health coverage for more than 25 million people.
CVS Health (CVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Adding these well-respected dividend payers to your portfolio could give you a stream of passive income that grows throughout your retirement years.
Key Insights Significantly high institutional ownership implies CVS Health's stock price is sensitive to their trading...
The healthcare industry is diverse and complex, with longtime staples and emerging disruptors to fit your portfolio -- and it also doesn't need to cost an arm and a leg. Here are several possibilities to consider, each playing a different role in the healthcare system. In an industry where size matters, Pfizer (NYSE: PFE) is one of the industry's most prominent players, with a market cap of over $200 billion.
Investors are optimistic about CVS Health (CVS) on continued growth across the entire range of insured and self-insured medical, pharmacy, dental and behavioral health products and services.
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
Alphabet, Raytheon, Blackstone, SAP SE and CVS Health are included in this Analyst Blog.
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Raytheon Technologies Corporation (RTX) and Blackstone Inc. (BX).
On Sunday, CVS Health (NYSE: CVS) revealed that it would be shuttering its clinical trial services segment by the end of 2024, according to reporting from biopharma industry trade publication Endpoints News. The pharmacy and health insurance giant began its foray into this space in 2021, and originally used its access to consumers to aid drugmakers in recruiting participants for COVID-19 vaccine trials and other coronavirus-related clinical investigations, but apparently, management doesn't feel that the business is contributing significantly to the company's prospects. Does this mean that CVS stock isn't as safe as shareholders have believed?
When CVS Health (NYSE: CVS) said on May 14 that it would exit its clinical trial services business after just two years in operation, management at Walgreens Boots Alliance (NASDAQ: WBA) was quick to confirm that it would still be moving forward full speed with building out its own service. Now, the smaller pharmacy chain will have the benefit of one less major competitor trying to work with drug developers to build out their clinical trials. Why bother to get into clinical trials in the first place?
Insiders have a longer-term holding horizon than most, a critical aspect that market participants should know. Nonetheless, seeing an insider step in and buy is always reassuring.
Laffer Tengler Investments CEO and CIO Nancy Tengler joins Yahoo Finance Live to discuss stocks to buy, including Starbucks, Chipotle, and Tesla, and stocks to avoid, including Disney and CVS.
Aetna Better Health of Virginia, a CVS Health company (NYSE: CVS), and Virginia Community Healthcare Association (VCHA) announced that Aetna provided a total of $7.3 million in value-based care incentive payments to 22 Federally Qualified Health Centers, also known as Community Health Centers, in Virginia. The funds aim to help health centers improve quality of care by enabling their population health management programs and increasing screenings for diabetes as well as breast, cervical and colo
All of these stocks offer reliable dividend payments that could help make your retirement dreams a reality.
Walgreens remains bullish on its clinical trials segment as rival CVS announces closure.
It is hard to get excited after looking at CVS Health's (NYSE:CVS) recent performance, when its stock has declined 24...
Many of the greatest investors of all time could be considered value investors. One stock that seems to be greatly undervalued right now is pharmacy chain and health insurer CVS Health (NYSE: CVS). Let's take a peek under the hood at its fundamentals and valuation to better understand why the stock could be a no-brainer buy for value investors this month and beyond.
Independent pharmacies and startups such as Cigna's Express Scripts and Mark Cuban's Cost Plus Drugs are partnering up to address a coverage gap for some Americans.
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Walmart (NYSE: WMT) is a large, well-funded, low-cost competitor that no company wants to go up against if they can avoid it. For big pharmacy retailers such as Walgreens Boots Alliance (NASDAQ: WBA) and CVS Health (NYSE: CVS), may soon find out what it feels like (even more than they already do). Walmart is a dominant name in retail as its low-priced merchandise draws in many consumers looking to save money, particularly now amid outsized and persistent inflation.
There's a story going around that retailers use customer donations to charity to line their own pockets. Keep reading to learn why that's not true.
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Shares of the healthcare giant are down more than 30% over the past six months, despite steadily growing profits from a rapidly growing collection of indispensable businesses.
The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make...